Rituximab in B-Cell Hematologic Malignancies: A Review of 20 Years of Clinical ExperienceGilles Salles(Memorial Sloan Kettering Cancer Center), David G. Maloney(Fred Hutch Cancer Center)Advances in TherapyOctober 1, 201710.1007/s12325-017-0612-xCited by 603SaveCiteExport RISWatch citationsRelated PapersThe International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee|Blood|2022|1.5kHematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects|Blood|2001|1.4kCD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4-1BB domains: pilot clinical trial results|Blood|2012|530Allografting with nonmyeloablative conditioning following cytoreductive autografts for the treatment of patients with multiple myeloma|Blood|2003|407Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL Younger): a randomised, open-label, phase 3 trial of the European Mantle Cell Lymphoma Network|The Lancet|2016|401